Prescription drug · BLA
Lunsumio Velo (Mosunetuzumab) NDC 50242-201
Mosunetuzumab 45 mg/mL · Injection · Subcutaneous · Genentech, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50242-201-01 | 50242020101 | 1 VIAL, GLASS in 1 CARTON (50242-201-01) / 1 mL in 1 VIAL, GLASSMarketed from Dec 19, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lunsumio Velo
- Generic name (nonproprietary)
- mosunetuzumab
- Active ingredients
- Mosunetuzumab — 45 mg/mL
- Dosage form
- Injection
- Route
- Subcutaneous
- Labeler
- Genentech, Inc.NDC labeler code 50242
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761263
- Marketing start
- Listing expires
- Identifiers
- Product ID 50242-201_cc3e8671-e1bd-494e-bedb-de8dc0e2f482SPL ID cc3e8671-e1bd-494e-bedb-de8dc0e2f482SPL set ID 6a2b6dc2-48bd-4da7-a611-bc6bae2893c8RxCUI 2729433, 2729436, 2729439, 2729442UNII LDJ89SS0YG
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450242020101followed by a unit qualifier and the quantityPackage 50242-0201-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
LUNSUMIO VELO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) 1.1 Follicular Lymphoma LUNSUMIO VELO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate [see Clinical …
Excerpt only. Read the full label for complete information.
About NDC 50242-201
- What is NDC 50242-201?
- 50242-201 is the product NDC for Lunsumio Velo (mosunetuzumab), Mosunetuzumab 45 mg/mL injection, listed with the FDA by Genentech, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Lunsumio Velo (Mosunetuzumab).
- What is the active ingredient?
- Mosunetuzumab.
- Who is the labeler?
- Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Lunsumio Velo?
- 1 other product NDC are listed under this name. See all Lunsumio Velo NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Lunsumio Velo products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Lunsumio Velomosunetuzumab | Mosunetuzumab 5 mg/.5mL | InjectionSubcutaneous | Genentech, Inc. | 50242-177 | 50242-0177-01 |
Other NDCs under BLA 761263
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Lunsumiomosunetuzumab | Mosunetuzumab 30 mg/30mL | ConcentrateIntravenous | Genentech, Inc. | 50242-142 |
| Lunsumiomosunetuzumab | Mosunetuzumab 1 mg/mL | ConcentrateIntravenous | Genentech, Inc. | 50242-159 |
| Lunsumio Velomosunetuzumab | Mosunetuzumab 5 mg/.5mL | InjectionSubcutaneous | Genentech, Inc. | 50242-177 |